131 related articles for article (PubMed ID: 35352655)
1. Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas.
Tutino F; Giovannini E; Pastorino S; Ferrando O; Giovacchini G; Ciarmiello A
Curr Radiopharm; 2022; 15(4):259-270. PubMed ID: 35352655
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL.
Zhao P; Yu T; Pan Z
Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
5. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
6. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
7. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic value of the metabolic volumetric parameters calculated with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Rodríguez Carrillo JL; Dotor de Lama A; Navarro Matilla MB; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):215-222. PubMed ID: 35469793
[TBL] [Abstract][Full Text] [Related]
11. Baseline
Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
[TBL] [Abstract][Full Text] [Related]
12. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of whole-body and spleen MTV (metabolic tumor volume) scanning for patients with diffuse large B cell lymphoma.
Yamanaka S; Miyagawa M; Sugawara Y; Hasebe S; Fujii T; Takeuchi K; Tanaka K; Yakushijin Y
Int J Clin Oncol; 2021 Jan; 26(1):225-232. PubMed ID: 33097970
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
15. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.
Frood R; Burton C; Tsoumpas C; Frangi AF; Gleeson F; Patel C; Scarsbrook A
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3198-3220. PubMed ID: 33604689
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Overall Survival and Progression-Free Survival by the
Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
[No Abstract] [Full Text] [Related]
17. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
18. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]